Scemblix (asciminib)

Numéro de dossier de l’APP: 21956
État des négociations:
Active Negotiation
Indication(s):
For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with two or more tyrosine kinase inhibitors
Promoteur/fabricant:
Novartis Pharmaceuticals Canada Inc.
Numéro de projet de l’ACMTS:
PC0275
Lettre-contrat de l’APP:
Conclusion du processus de négociation:
Not Applicable